Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients

Recruiting now

Conditions studied: Cytopenia, MDS

In brief

This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing.

Key facts

Study ID

NCT07081087

Run by

Weizmann Institute of Science

People needed

1500

Starts

2025-06-01

Expected to finish

2028-12-01

Last updated by the study team

2026-03-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged 18 and up with suspected/confirmed MDS cases referred to BM evaluation either for diagnosis or risk assessment due to cytopenia
• Platelets < 150 × 10E9/L or
• Absolute neutrophil count < 1.8 × 10E9/L or
• Hemoglobin (Hgb) < 13 g/dL (males) and < 12 g/dL (female) and
• For both sexes, no evidence of Iron, folinic acid, or B12 deficiency

You may not qualify if…

• Women who are pregnant
• Previous diagnosis of leukemia; AML, MPN, ALL, CLL, MGUS/MM or any other gammopathy
• Lymphocytes > 5000/ul
• Patients who are on disease-related therapy are excluded, unless they are treated with Erythropoietin or Prednisone. See Appendix 2 for the list of excluded treatments.
• Patients who have undergone a bone marrow transplant.

Where it is running

• University of California San Diego — San Diego, California, United States (enrolling)
• University of Miami — Miami, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.